PRA International knows it takes more than laboratory research to get drugs approved. The company is a clinical research organization (CRO) that provides an array of drug development services to pharmaceutical and biotechnology companies around the world. Services it offers include clinical trials management, drug safety and risk management, database development, and regulatory filing preparation. PRA's clients are engaged in most major therapeutic areas, but the company's particular strengths lie in cardiovascular disease, infectious diseases, neurology, oncology, and respiratory and allergy disorders.
PRA conducts Phase I-IIa studies in its clinics in Europe and the US. It operates two bioanalytical laboratories, one in Europe (Assen, The Netherlands) and one in North America (Lenexa, Kansas). To date, the company contributed to more than 35 drug approvals across a range of therapeutic areas.
PRA has supported more than 3,100 clinical trials in more than 80 countries on 6 continents through its more than 40 global offices.
PRA's success depends on the size of the R&D budgets of its pharmaceutical and biotech clients. The company has benefited from the growth of biotechnology spending as a proportion of overall drug R&D (since biotechs are more likely to outsource drug development) and an increased number of products entering clinical trials in recent years. In 2012 the company signed an agreement with Amgen providing full service support to the development pipelines of PRA's clients.
PRA has extended its geographical reach into emerging markets as well as in Europe. In 2011 PRA opened a new office in Bucharest, Romania to further strengthen its coverage of the Balkan region's burgeoning markets, which was followed by expansion of its operations in the Netherlands and the UK to accommodate staff growth and strong client demand for its Phase IIa-IIIb service offerings.. In 2012 it also opened an office in China to accommodate its continued expansion in Asia and the Asia-Pacific regions.
In 2011 PRA acquired Indian software developer and services company Kinship Technologies. With the acquisition comes Kinship's flagship product EXACT, which allows users to construct reusable programs for data extraction, data transformation, statistical reporting, and electronic publishing in a visual environment with limited code writing.
PRA is owned by private equity firm Genstar Capital, which took it private in 2007. – less